Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Non-Current Assets (2019 - 2025)

aTYR PHARMA's Non-Current Assets history spans 7 years, with the latest figure at $12.8 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 14.18% year-over-year to $12.8 million; the TTM value through Dec 2025 reached $54.4 million, down 12.44%, while the annual FY2025 figure was $12.8 million, 14.18% down from the prior year.
  • Non-Current Assets reached $12.8 million in Q4 2025 per ATYR's latest filing, down from $13.6 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $18.3 million in Q2 2023 to a low of $1.7 million in Q1 2022.
  • Average Non-Current Assets over 5 years is $11.4 million, with a median of $14.0 million recorded in 2025.
  • Peak YoY movement for Non-Current Assets: tumbled 44.59% in 2022, then skyrocketed 948.28% in 2023.
  • A 5-year view of Non-Current Assets shows it stood at $2.0 million in 2021, then soared by 657.88% to $14.9 million in 2022, then rose by 18.41% to $17.7 million in 2023, then decreased by 15.77% to $14.9 million in 2024, then fell by 14.18% to $12.8 million in 2025.
  • Per Business Quant, the three most recent readings for ATYR's Non-Current Assets are $12.8 million (Q4 2025), $13.6 million (Q3 2025), and $14.0 million (Q2 2025).